Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: J Invest Dermatol. 2023 Feb 24;143(8):1579–1590.e5. doi: 10.1016/j.jid.2023.01.027

Figure 6: Low m6Ascore predicts better efficacy of melanoma checkpoint immunotherapy.

Figure 6:

(a) Survival analyses based on high and low m6A of 47 patients in the anti-PD-1 therapy cohort (BMS038) show low m6Ascore is significantly associated with better anti-PD-1 response (HR, 3.48; 95% CI, 1.05–11.51; p = 0.032). (b) The percentage of patients with anti-PD-1 response in the high and low m6Ascore in BMS038 show progressive disease, and stable disease (PD/SD) patients are greater in the high m6Ascore, and complete responder or partial responder (CR/PR) patients are greater in the low m6Ascore. (c) Difference of m6Ascore in distinct anti-PD-1 clinical response groups show PD/SD patients’ m6Ascores are significantly higher than CR/PR patients’. (d) Differences in the expression of CTLA4 among high and low m6Ascore in anti-CTLA4 cohorts (GSE63557) (p = 0.0091, Wilcoxon test). (e) The percentage of patients with anti-CTLA4 response in the high and low m6Ascore. NR: non-responder; R: responder. (f) Difference of m6Ascore in distinct anti-CTLA4 clinical response groups. NR patients’ m6Ascores are significantly higher than R patients’. (g) Survival analyses based on high and low m6Ascore in IFN-α therapy cohort (TCGA-SKCM). Low m6Ascore is significantly associated with a better IFN-α response (HR, 15.49; 95% CI, 0.97–247.80; p = 0.0092). (h) The percentage of patients with IFN-α response in the high and low m6Ascore. NR: non-responder; R: responder. (i) Difference of m6Ascore in distinct IFN-α clinical response groups. NR patients’ m6Ascores are significantly higher than R patients’.